Abstract
Diabetes mellitus is known to be one of the most challenging public health issues of the 21st century. The unwanted side effects associated with conventional synthetic antidiabetic medications have compelled the quest for natural antidiabetic drugs. Therefore, in this study, in vitro, in vivo, and in silico antidiabetic effects of Zingiber capitatum methanol extract (ZcME) were evaluated. ZcME exhibited potent inhibitory activity against α-glucosidase as evidenced by an IC50 value of 0.45 mg/ml compared to standard voglibose (IC50 = 0.31 mg/ml). The administration of ZcME at 400 mg/kg significantly (p < 0.05) reduced the fasting blood glucose level compared to the diabetic control group after 20 days of treatment. ZcME decreased blood glucose levels 25.80% on day 1, 45.58% on day 10, and up to 59.17% on day 20 when given at 400 mg/kg BW. Furthermore, GC–MS examination of the plant extracts revealed the presence of sterols, aliphatic acids, aromatics, and esters. In silico study affirm the experimental findings, where the identified compounds showed strong binding affinities against α-glucosidase (7.9 kcal/mol), α-amylase (9.7 kcal/mol), and glycogen phosphorylase enzymes (7.7 kcal/mol), highlighting the antidiabetic potential of ZcME.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.